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Protein precipitationAbstract This study presents the optimization of a simple HPLC-UV method for the determina-
tion of metformin in human plasma. Ion pair separation followed by UV detection was performed
on deproteinized human plasma samples. The separation was carried out on a Discovery Reversed
Phase C-18 column (250 · 4.6 mm, 5 lm) with UV detection at 233 nm. The mobile phase contained
34% acetonitrile and 66% aqueous phase. Aqueous phase contained 10 mM KH2PO4 and 10 mM
sodium lauryl sulfate. Aqueous phase pH was adjusted to 5.2. The mobile phase was run isocrati-
cally. The ﬂow rate of the mobile phase was maintained at 1.3 ml/min. The linearity of the calibra-
tion curve was obtained in the concentration range of 0.125–2.5 lg/ml and coefﬁcient of
determination (R2) was found to be 0.9951. The lowest limit of quantiﬁcation and detection was
125 and 62 ng/ml respectively. No endogenous substances were found to interfere with the peaks
of drug and internal standard. The intra-day and inter-day coefﬁcient of variations was 6.97%
or less for all the selected concentrations. The relative errors at all the studied concentrations were
5.60% or less. This method is time efﬁcient and samples are easy to prepare with minimum dilution.
So, it can be applied for monitoring metformin in human plasma.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Metformin was developed from a herb Galega ofﬁcinalis and it
was synthesized in 1922 in Dublin as a blood glucose lowering
agent (Shenﬁeld, 2013). It has been widely prescribed world-
wide since it was introduced in clinical practice in 1957.
Currently metformin has been used as the ﬁrst line therapy
in the treatment of type 2 diabetes mellitus patients (Nathan
et al., 2009). Also, metformin is now used to treat polycystic
ovary syndrome, gestational diabetes and is showing early
promise as a treatment for cancer. It is advantageous in
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Figure 1 Chemical structure of metformin hydrochloride.
Figure 2 Sample preparation procedure.
484 H.P. Chhetri et al.diabetic subjects who are overweight and also has further
potential advantages in patients with the metabolic syndrome
where hyperinsulinaemia is present (Campbel and Howlett,
1995). Major clinical beneﬁts of metformin over sulfonylureas
are that (1) therapeutic doses of metformin do not cause hypo-
glycemia, (2) metformin does not lower blood glucose in
non-diabetic individuals and (3) metformin has direct beneﬁ-
cial effects on serum lipids and lipoproteins (Klip and Leiter,
1990). It reduces blood glucose levels, predominantly by
improving hepatic and peripheral tissue sensitivity to insulin
without affecting the secretion of insulin.
Chemically, metformin hydrochloride is N, N-dimethylimi-
docarbonimidic diamide hydrochloride (Klepser and Kelly,
1997) and has the structural formula as shown in Fig. 1.
Metformin is a small highly polar molecule (pKa = 2.8,
11.5, logP octanol: water = 2.6) which has great solubility
in water and poor solubility in lipids so it is very difﬁcult to ex-
tract it from the aqueous plasma matrix (Georgita et al., 2010).
There are many methods reported to analyze metformin
hydrochloride in plasma by HPLC (AbuRuz et al., 2003;
AbuRuz et al., 2005; Gabr et al., 2010; Ranetti et al., 2009;
Yardimci et al., 2007; Yuen and Peh, 1998). Those reported
methods use gradient mobile phases, use the solid phase
extraction technique or have a very complex and multiple step
protein extraction technique that make the analysis of large
numbers of sample difﬁcult, costly and time consuming. Some
do not use internal standards while the others dilute the sample
excessively and require nitrogen drying. So there is a need for a
sensitive, fast and easy method to determine metformin hydro-
chloride in plasma. This research was conducted to optimize
an easy, sensitive and time efﬁcient method for the quantiﬁca-
tion of metformin hydrochloride in human plasma by HPLC
using UV detection. The plasma samples are diluted minimally
during sample pretreatment so the volume of sample required
to be injected is small. The plasma sample requires only a one
step protein precipitation that makes the method faster and
easier.
2. Experimental
2.1. Reagents and chemicals
Perchloric acid 60% solution m/m, potassium dihydrogen
phosphate, sodium dodecyl (lauryl) sulfate and acetonitrile
were purchased from Ferak Germany, Merck Germany, AC-
ROS Organics and VWR Prolabo Belgium respectively.
Metformin hydrochloride was obtained from ABC chemicals
and phenytoin sodium from FAGRON Belgium. The lyophi-
lized human plasma was purchased from SIGMA–AL-
DRICH, Belgium.
2.2. Instrumentations
The LC system consisted of a pump (Merck Hitachi L-6200
intelligent pump) with auto sampler (Spectra SERIES AS100) having 50 and 20 ll injectors. The detector used was a
UV–vis (ELITE Lachrom Hitachi L-2400 model). The wave-
length was set at 233 nm. The software used was Chromeleon.
The column used was Discovery Reversed Phase C-18
(250 · 4.6 mm, 5 lm). Vortex-2 Genie and MiniSpin plus
(Eppendorf) were used to vortex and centrifuge plasma sam-
ples respectively.
2.3. Mobile phase preparation
The mobile phase contained 34% acetonitrile and 66% aque-
ous phase. The aqueous phase contained 10 mM KH2PO4
and 10 mM sodium lauryl sulfate. The pH of aqueous phase
was adjusted to 5.2 by using dilute orthophosphoric acid.
The mobile phase was run isocratically. The ﬂow rate of the
mobile phase was maintained at 1.3 ml/min. Injection volumes
were 20 ll. The mobile phase was degassed by using helium gas
prior to its use. The HPLC column was kept at ambient
temperature.
2.4. Preparation of standard and sample solutions
Stock solution of metformin hydrochloride was prepared by
dissolving 20 mg of metformin hydrochloride in methanol
(200 lg/ml) and the ﬁnal volume was made to 100 ml with
the same solvent. Similarly phenytoin sodium, the internal
standard, was also prepared by dissolving 20 mg in 100 ml
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Figure 4 Chromatogram of plasma samples spiked with phe-
nytoin sodium and metformin HCl.
Simple HPLC-UV method for the quantiﬁcation of metformin 485methanol (200 lg/ml). The stock solution of metformin hydro-
chloride was diluted with methanol to prepare working
solutions having the concentrations of 25, 20, 10, 5, 2.5 and
1.25 lg/ml respectively.
2.5. Plasma sample preparation for the determination of
metformin hydrochloride
380 ll of human plasma was transferred into a 1.5 ml eppen-
dorf tube. 50 ll each of drug and internal standard solutions
were added to the plasma and vortex mixed for 1 min. Then
20 ll of perchloric acid (60% m/m) was added and vortex
mixed for 1 min and the mixture was centrifuged at 9400g
for 3 min (Fig. 2). The supernatant layer was transferred into
another tube and ﬁltered through a 0.45 lm ﬁlter. A 20 ll of
the ﬁltrate was injected onto the HPLC column.
3. Results and discussion
The developed HPLC method was optimized for the analysis
of metformin hydrochloride in human plasma. Different
mobile phases were tested to ﬁnd the best condition to quantify
metformin hydrochloride in plasma. Different ratios of meth-
anol, acetonitrile, sodium lauryl sulfate and potassium dihy-
drogen phosphate were tried and the optimum mobile phase
was ﬁnalized. Then the method was validated for selectivity,
linearity, limit of quantiﬁcation, accuracy, precision and recov-
ery as per the international guidelines (FDA guideline, 2001).
3.1. Selectivity
Selectivity is the ability of an analytical method to differentiate
and quantify the analyte in the presence of other components
in the sample. Six plasma samples were chromatographed to
check for endogenous components which might interfere with
metformin hydrochloride and internal standard (phenytoin so-
dium). Spiked plasma samples representing a low (0.25 lg/ml),
medium (1 lg/ml) and high (2.5 lg/ml) metformin hydrochlo-
ride concentration were analyzed to verify the selectivity of the
method of analysis. Both the peaks of phenytoin sodium and
metformin hydrochloride did not interfere with any endoge-
nous components. There was also a very good resolution
between the peaks of phenytoin and drug (Figs. 3 and 4).0.0 2.0 4.0 6.0 8.0 10.0 12.0 15.0
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Figure 3 Chromatogram of blank plasma.The resolution between metformin and phenytoin is 9.7 and
the resolution between metformin and the closest matrix peak
is 5.6. These values conﬁrm that the method is selective. The
mean retention time of phenytoin and metformin was found
to be 7.56 ± 0.01 min and 9.93 ± 0.01 min respectively.
3.2. Linearity
The linearity was determined from the constructed standard
calibration curve. The upper limit of the range was taken as
2.5 lg/ml since the plasma concentration of metformin is lower
than this value after its oral administration. Six non-zero sam-
ples (0.125, 0.250, 0.5, 1, 2, and 2.5 lg/ml) including the lower
limit of quantiﬁcation (LLOQ i.e. 0.125 lg/ml) were used to
draw the standard calibration curve (n= 3).
The calibration curve was obtained by plotting chromato-
graphic peak area ratios (metformin/phenytoin) versus
concentration of metformin hydrochloride (Fig. 5). Samples
were prepared and injected same day. The calibration curve
was linear in the given range (R2 = 0.9951).
3.3. Lower limit of quantiﬁcation (LLOQ) and lower limit of
detection (LLOD)
The analyte concentration that produced a signal to noise ratio
greater than 5 and 3 was considered as the LLOQ and LLOD
respectively. The LLOQ and LLOD as per these criteria were
found to be 0.125 and 0.062 lg/ml when 20 ll of sample was
injected. But when the injection volume was increased toCalibration curve
y = 0.8743x + 0.0428
R2 = 0.9951
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Table 1 Intra-day and inter-day accuracy and precision data (n= 5).
Conc. added (lg/ml) Conc. calculated Std. deviation % Coeﬃcient of variation (CV) % Relative error (RE)
Intra-day Inter-day Intra-day Inter-day Intra-day Inter-day Intra-day Inter-day
0.5 0.49 0.51 0.001 0.04 0.21 6.97 2.00 2.00
1 1.04 1.03 0.05 0.06 4.54 5.98 4.00 3.00
2.5 2.62 2.64 0.05 0.06 2.01 2.30 4.80 5.60
0.0 2.0 4.0 6.0 8.0 10.0 12.0 15.0
-10.0
-5.0
0.0
5.0
10.0
15.0
20.0
25.0
C
ur
re
nt
 [n
A]
Retention Time [min]
7.
51
1
9.
54
2Phenytoin     
Metformin 
Figure 6 Chromatogram after plasma protein precipitation with
acetonitrile.
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486 H.P. Chhetri et al.50 ll, the LLOQ was further reduced to 0.031 lg/ml. So, this
method was found to be sensitive enough to apply for bioavail-
ability studies.
3.4. Accuracy and precision
The accuracy of the analytical method describes the closeness
of the mean test results obtained by the method to the true
value of the analyte whereas precision is the closeness of indi-
vidual measures of an analyte when the procedure is applied
repeatedly to multiple aliquots of a single homogeneous vol-
ume of biological matrix. For accuracy the mean value of three
concentrations should be within 15% of the actual value and
for the precision the coefﬁcient of variation (CV) should not
exceed 15% at each concentration level (FDA guideline, 2001).
The intra-day and inter-day degree of precision and accu-
racy of the method is expressed as coefﬁcient of variation
and relative error respectively (Table 1). The intra-day and
inter-day coefﬁcient of variations was 6.97% or less for all
the selected concentrations. The relative errors at all the stud-
ied concentrations were 5.60% or less. These data indicate a
considerable degree of precision and accuracy of the method
both during the analytical run and between different runs.
The relative error shows that the method is remarkably
accurate which ensures that reliable results are obtained.
3.5. Recovery
Recovery is the detector response obtained from an amount of
the analyte added to and extracted from the biological matrix,
compared to the detector response obtained for the true con-
centration of the pure authentic standard (FDA guideline,
2001). Recovery pertains to the extraction efﬁciency of an ana-
lytical method within the limits of variability. A single stage
extraction using 20 ll of 60% m/m perchloric acid was used
for the protein precipitation of 380 ll plasma. This minimal
volume does not dilute the drug which ultimately improved
the sensitivity of this technique. This method gave a good
recovery with a minimal time for extraction (Table 2).
The metformin was found to be stable during storage and
during all steps of the analytical method. For the protein
extraction from plasma, acetonitrile and methanol were alsoTable 2 Recovery of metformin hydrochloride at three
concentrations (n= 3).
Conc. added (lg/ml) Mean recovery ± SD %RSD
0.5 102.32 ± 8 7.82
1 98 ± 3.09 3.12
2.5 105.89 ± 1.79 1.69tried but the protein precipitation was not complete and there
were interfering peaks as well (Figs. 6 and 7). The ratio of plas-
ma and acetonitrile was 1:1.5. Methanol was also used in the
same ratio. As mentioned above, the precipitation of plasma
proteins with organic solvents was insufﬁcient. Increasing the
volume of organic solvent would dilute the drug in the sample
and adversely affect the sensitivity. Previous methods that used
a protein precipitation or liquid–liquid extraction procedure
with a column speciﬁcally designed for reversed phase chroma-
tography used an injection volume of 100 ll or more (Gabr
et al., 2010). So the modiﬁcation of the previous method
(Zarghi et al., 2003) by using perchloric acid reduced the0.0 2.0 4.0 6.0 8.0 10.0 12.0 15.0
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Figure 7 Chromatogram after plasma protein precipitation with
methanol.
Simple HPLC-UV method for the quantiﬁcation of metformin 487dilution of the sample and also the volume of injection (20 ll)
but the method still remained sensitive.
4. Conclusion
The optimized HPLC-UV method is selective, accurate, precise
and repeatable. The method is linear over a wide range and
utilizes a mobile phase which can be easily prepared. The
column used is a widely available reversed phase C-18. The
run time is short and protein precipitation technique is very
simple. Even for an injection volume of 20 ll the method is
quite sensitive. It can be concluded that the method is suitable
for the routine quantiﬁcation of metformin in human plasma.
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